C3 and periodontitis: In previous studies, AMY-101, a novel complement inhibitor with potential for the treatment of periodontitis, has shown remarkable potential in the clinical treatment of periodontitis (52), effectively reducing inflammatory responses and tissue damage (53), improving periodontal health by inhibiting the C3 component of the complement system, and demonstrating a good safety and tolerability profile (Table 1).